Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs placebo
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint… 2023 · Cochrane Headline outcomes onlyRR 0.31 [0.08, 1.22]2 studies · 101 participantsVery low